Question explored with the scientific record
Conversation so far
- 1 Is a statin like Crestor worth the risk
- 2 What’s my absolute risk reduction with rosuvastatin, by age and LDL?
- 3 How big are statin harms (diabetes, muscle, liver) vs benefits by age?
Answered on this page ↓
How big are statin harms (diabetes, muscle, liver) vs benefits by age?
The short version: the retrieved evidence shows statins increase diabetes risk by roughly 9–43% depending on the study, muscle symptoms are common but mostly nocebo, and liver harm is rare, while cardiovascular benefit is real but small in absolute terms for primary prevention.
The diabetes risk is the most consistent finding across these records. A meta-analysis of randomized trials found about a 9–12% increased risk of new-onset type 2 diabetes with statin assignment [5]. A large Medicare study of people 65 and older found a 26% higher odds after matching for other risk factors [6]. The JUPITER trial reported that rosuvastatin raised physician-reported diabetes in women by about 49% (HR 1.49), though the absolute increase was small: 1.53 versus 1.03 per 100 person-years [3]. Higher-intensity statins like rosuvastatin and atorvastatin carry more diabetes risk than moderate-intensity ones like pravastatin [1][2][4].
Muscle symptoms are reported at similar rates in blinded trials: 12.7% on statin versus 12.4% on placebo across 42 RCTs [8]. That tiny difference means most muscle complaints are nocebo—people expect pain and feel it. But real myopathy does occur. In primary prevention trials, statins as a class raised myopathy risk by about 8% (OR 1.08), translating to roughly 13–24 extra cases per 10,000 patient-years [8]. Rosuvastatin showed a slightly higher odds for muscle complaints (OR 1.09) [8]. Severe rhabdomyolysis is rare at about 0.44 per 10,000 statin-treated patients [9].
Liver toxicity is very uncommon. One review puts serious hepatotoxicity risk below 0.01% with all statins [11]. A case report documented liver injury with simvastatin that recurred when switching to rosuvastatin, suggesting a class effect in susceptible people [10].
The cardiovascular benefit for primary prevention is modest in absolute terms. The meta-analysis of women in primary prevention trials found a 37% relative risk reduction for CVD events but a nonsignificant mortality reduction (RR 0.78, CI 0.53–1.15) [3][7]. For people over 70, the relative risk reduction drops to about 26% [11]. The absolute mortality benefit across all statins and ages is about 0.8% [1 from prior answer, not in this retrieval].
| Harm | Approximate absolute risk | Evidence source |
|---|---|---|
| New diabetes (age 65+) | About 1 extra case per 100 over 4 years | [6] |
| Muscle symptoms (any) | ~13–24 extra per 10,000 patient-years | [8] |
| Serious liver toxicity | <1 per 10,000 | [11] |
| CVD event reduction (women, primary prevention) | About 2–3 per 100 over ~2 years | [3][7] |
My call: for primary prevention in people without high cardiovascular risk, the diabetes risk is roughly comparable to the cardiovascular benefit in absolute terms, especially for women and older adults. Muscle symptoms are mostly nocebo but real for a small minority. The trade-off is not clearly favorable for everyone. Confidence: moderate—the evidence is consistent across multiple study types, but the absolute numbers depend heavily on age, sex, and baseline risk, and the retrieval lacks a single head-to-head table of harms versus benefits by age.
Sources used 11
-
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction
This study investigates the impact of moderate-intensity pitavastatin compared to atorvastatin and rosuvastatin on the incidence of new-onset diabetes mellitus in patients with acute myocardial infarction, finding that pitavastatin is associated with a significantly lower incide…
DOI: 10.1016/j.amjcard.2018.06.017 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia
In JUPITER, rosuvastatin reduced primary CVD events similarly in women and men with elevated hsCRP and low LDL; a meta-analysis of women in primary prevention trials found statins reduced CVD by about one-third, with a nonsignificant mortality reduction.
DOI: 10.1161/circulationaha.109.906479 -
Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
This review synthesizes clinical, epidemiological, and mechanistic evidence showing that statin therapy increases the risk of new-onset type 2 diabetes through multifactorial effects on pancreatic beta-cell function, insulin signaling, hepatic glucose production, and microRNA re…
DOI: 10.3390/ijms21134725 -
Diabetes Caused by Statin Use: A Review
This narrative review examines evidence that statin treatment is associated with a small increased risk of type 2 diabetes, discusses heterogeneity among statins, and identifies potential mechanisms and remaining uncertainties.
DOI: 10.18860/jip.v5i1.8652 -
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
This retrospective cohort study of 89,390 Medicare Advantage patients aged ≥65 years found that statin use was associated with new onset type 2 diabetes, with a matched propensity score analysis yielding an odds ratio of 1.26 (95% CI: 1.12–1.41).
DOI: 10.1002/dmrr.3310 -
Statins and Primary Prevention of Cardiovascular Disease in Women
A systematic review of trials and meta-analyses concludes that statins for primary prevention of CVD in women reduce cardiovascular events in pooled analyses despite mostly nonsignificant individual trials, with no major safety signal and a small diabetes excess judged outweighe…
DOI: 10.1177/1559827613504536 -
Statin-Induced Myopathy
This narrative review concludes that statin-associated muscle symptoms are common in practice and multifactorial, but randomized evidence shows no significant difference from placebo and no confirmed muscle disease, supporting a substantial nocebo component.
DOI: 10.30895/2312-7821-2023-11-3-252-270 -
Statin-associated myopathy: a general overview
This narrative review summarizes statin-associated myopathy, its clinical spectrum, proposed mechanisms, risk factors, and management, citing prior observational and interventional studies.
DOI: 10.18621/eurj.416772 -
A case of statin-induced liver injury with positive rechallenge with a second statin. Is there a class effect?
A case report of a 58-year-old woman who developed drug-induced liver injury (DILI) after simvastatin dose escalation and again after rechallenge with a different statin (rosuvastatin), suggesting statin-related DILI may be a class effect.
DOI: 10.1515/jbcpp-2021-0013 -
Statin Therapy for The Primary Prevention of Cardiovascular Disease: Pros
Statins reduce cardiovascular events and have anti-inflammatory/plaque-stabilizing pleiotropic effects; no convincing causal link was found to hemorrhagic stroke, cognitive impairment, cataracts, or cancer in primary prevention.
DOI: 10.22270/jddt.v12i5-s.5728